LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements
LIXTE Biotechnology Holdings (NASDAQ:LIXT) has successfully regained compliance with Nasdaq's minimum equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market. The compliance was achieved through two recent fundraising events: a $5.0 million placement and a $1.5 million registered direct offering completed on July 2 and July 8, 2025, respectively.
The clinical stage pharmaceutical company is currently conducting trials in ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. CEO Geordan Pursglove emphasized the company's commitment to maintaining its Nasdaq listing while advancing its clinical programs.
LIXTE Biotechnology Holdings (NASDAQ:LIXT) ha riconquistato con successo la conformità al requisito minimo di capitale proprio di 2,5 milioni di dollari per la permanenza nel Nasdaq Capital Market. Il raggiungimento della conformità è avvenuto grazie a due recenti operazioni di raccolta fondi: un collocamento da 5,0 milioni di dollari e un offerta diretta registrata da 1,5 milioni di dollari completate rispettivamente il 2 e l'8 luglio 2025.
La società farmaceutica in fase clinica sta attualmente conducendo studi su carcinoma a cellule chiare ovarico, cancro colon-rettale metastatico e sarcoma dei tessuti molli avanzato. Il CEO Geordan Pursglove ha sottolineato l'impegno dell'azienda nel mantenere la quotazione al Nasdaq e nel portare avanti i suoi programmi clinici.
LIXTE Biotechnology Holdings (NASDAQ:LIXT) ha recuperado con éxito el cumplimiento del requisito mínimo de capital de 2,5 millones de dólares para mantener su cotización en el Nasdaq Capital Market. Este cumplimiento se logró mediante dos recientes eventos de recaudación de fondos: una colocación de 5,0 millones de dólares y una oferta directa registrada de 1,5 millones de dólares completadas el 2 y el 8 de julio de 2025, respectivamente.
La compañía farmacéutica en fase clínica está llevando a cabo ensayos en carcinoma de células claras de ovario, cáncer metastásico de colon y sarcoma de tejidos blandos avanzado. El CEO Geordan Pursglove destacó el compromiso de la empresa para mantener su cotización en Nasdaq mientras avanza en sus programas clínicos.
LIXTE Biotechnology Holdings (NASDAQ:LIXT)는 나스닥 캐피털 마켓 상장을 유지하기 위한 최소 자본 요건인 250만 달러를 성공적으로 충족했습니다. 이 요건 충족은 2025년 7월 2일과 7월 8일 각각 완료된 500만 달러 배정과 150만 달러 등록 직접 공모 두 건의 최근 자금 조달을 통해 이루어졌습니다.
임상 단계의 제약 회사인 이 기업은 현재 난소 투명 세포암, 전이성 대장암, 진행성 연부 조직 육종에 대한 임상 시험을 진행 중입니다. CEO인 Geordan Pursglove는 임상 프로그램을 발전시키는 동시에 나스닥 상장 유지에 대한 회사의 의지를 강조했습니다.
LIXTE Biotechnology Holdings (NASDAQ:LIXT) a réussi à se conformer à l'exigence minimale de fonds propres de 2,5 millions de dollars pour maintenir sa cotation sur le Nasdaq Capital Market. Cette conformité a été obtenue grâce à deux levées de fonds récentes : un placement de 5,0 millions de dollars et une offre directe enregistrée de 1,5 million de dollars, finalisées respectivement les 2 et 8 juillet 2025.
La société pharmaceutique en phase clinique mène actuellement des essais sur le carcinome à cellules claires de l'ovaire, le cancer du côlon métastatique et le sarcome des tissus mous avancé. Le PDG Geordan Pursglove a souligné l'engagement de l'entreprise à maintenir sa cotation au Nasdaq tout en faisant progresser ses programmes cliniques.
LIXTE Biotechnology Holdings (NASDAQ:LIXT) hat erfolgreich die Einhaltung der Mindestkapitalanforderung von 2,5 Millionen US-Dollar für die Fortsetzung der Notierung am Nasdaq Capital Market wiedererlangt. Diese Einhaltung wurde durch zwei kürzliche Finanzierungsmaßnahmen erreicht: eine 5,0 Millionen US-Dollar Platzierung und ein 1,5 Millionen US-Dollar registriertes Direktangebot, die am 2. und 8. Juli 2025 abgeschlossen wurden.
Das Pharmaunternehmen in der klinischen Phase führt derzeit Studien zu klarzelligem Ovarialkarzinom, metastasiertem Darmkrebs und fortgeschrittenem Weichteilsarkom durch. CEO Geordan Pursglove betonte das Engagement des Unternehmens, die Nasdaq-Notierung aufrechtzuerhalten und gleichzeitig seine klinischen Programme voranzutreiben.
- Successfully raised $6.5 million through combined offerings
- Regained compliance with Nasdaq listing requirements
- Maintains active clinical trials in three cancer indications
- Recent fundraising activities may lead to shareholder dilution
- Previously failed to meet Nasdaq's minimum equity requirement
PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has received a letter from the Nasdaq Hearings Panel stating that the Company has regained compliance with Nasdaq’s Listing Rule 5550(b)(1), the “Equity Rule,” requiring a minimum equity requirement of
The Nasdaq letter follows LIXTE’s closing of a
Geordan Pursglove, LIXTE’s Chief Executive Officer, said, “Regaining compliance underscore’s the Company’s dedication to its Nasdaq listing and to fostering LIXTE’s financial health, as it continues to pursue its promising clinical trials in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma, among other opportunities.”
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about LIXTE, contact:
info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
FAQ
What did LIXTE Biotechnology (LIXT) announce regarding Nasdaq compliance?
How much funding did LIXTE Biotechnology raise in July 2025?
What clinical trials is LIXTE Biotechnology currently conducting?
Who is the CEO of LIXTE Biotechnology Holdings?
What is the stock symbol for LIXTE Biotechnology Holdings?
